Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas

Nature Communications

Volumn 4, Issue , 2013, Pages

  Kim, Il Jin ^a,b   Quigley, David ^b   To, Minh D ^a,b   Pham, Patrick ^a   Lin, Kevin ^b   Jo, Brian ^b   Jen, Kuang Yu ^b   Raz, Dan ^a   Kim, Jae ^a   Mao, Jian Hua ^c   Jablons, David ^a,b   Balmain, Allan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; NKX 2-1 PROTEIN; PHOSPHOTRANSFERASE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VACCINIA RELATED KINASE;

CELL ORGANELLE; CORRELATION; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ANALYSIS; INHIBITION; TUMOR;

AMINO ACID METABOLISM; ARTICLE; CELL GROWTH; CELL LINEAGE; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; MITOSIS; SIGNAL TRANSDUCTION;

EID: 84877774804     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2660     Document Type: Article

References (60)

1. Edwards, B. K. et al. Annual Report to the Nation on the Status of Cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544-573 (2010).
2. Delbaldo, C. et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst. Rev. 17, CD004569 (2007).
3. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
4. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
5. Quigley, D. A. et al. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 458, 505-508 (2009).
6. Quigley, D. A. et al. Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol. 12, R5 (2011).
7. Lum, P. Y. et al. Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J. Neurochem. 97, 50-62 (2006).
8. Mehrabian, M. et al. Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits. Nat. Genet. 37, 1224-1233 (2005). (Pubitemid 41568705)
9. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007). (Pubitemid 350231325)
10. Kwei, K. A. et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27, 3635-3640 (2008). (Pubitemid 351793793)
11. Kolla, V. et al. Thyroid transcription factor in differentiating type II cells: regulation, isoforms, and target genes. Am. J. Respir. Cell Mol. Biol. 36, 213-225 (2007). (Pubitemid 46233475)
12. Khoor, A., Whitsett, J. A., Stahlman, M. T., Olson, S. J. & Cagle, P. T. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum. Pathol. 30, 695-700 (1999). (Pubitemid 29266730)
13. Guillot, L. et al. NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in 'Brain-Lung-Thyroid Syndrome'. Hum. Mutat 31, E1146-E1162 (2010).
14. Doyle, D. A., Gonzalez, I., Thomas, B. & Scavina, M. Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J. Pediatr. 145, 190-193 (2004). (Pubitemid 38993390)
15. Garcia, R., Grindlay, J., Rath, O., Fee, F. & Kolch, W. Regulation of human myoblast differentiation by PEBP4. EMBO Rep. 10, 278-284 (2009).
16. Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl Acad. Sci. USA 91, 5657-5661 (1994). (Pubitemid 24174387)
17. Anderegg, U. et al. MEL4B3, a novel mRNA is induced in skin tumours and regulated by TGF-beta and pro-inflammatory cytokines. Exp. Dermatol. 14, 709-718 (2005). (Pubitemid 41150367)
18. Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765 (2009).
19. Wang, J. B. et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18, 207-219 (2010).
20. McKay, J. D. et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 40, 1404-1406 (2008).
21. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221-227 (2009).
22. Hsiung, C. A. et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet. 6, e1001051 (2010).
23. Possemato, R. et al. Suppression of hPOT1 in diploid human cells results in an hTERT-dependent alteration of telomere length dynamics. Mol. Cancer Res. 6, 1582-1593 (2008).
24. Lee, J. et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 27, 3754-3760 (2008). (Pubitemid 351912970)
25. Girdler, F. et al. Validating Aurora B as an anti-cancer drug target. J. Cell Sci. 119, 3664-3675 (2006). (Pubitemid 44501870)
26. Fu, S., Hu, W., Kavanagh, J. J. & Bast, Jr R. C. Targeting Aurora kinases in ovarian cancer. Expert Opin. Ther. Targets 10, 77-85 (2006). (Pubitemid 43263268)
27. Warner, S. L., Bearss, D. J., Han, H. & Von Hoff, D. D. Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. 2, 589-595 (2003).
28. Ko, M. A. et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat. Genet. 37, 883-888 (2005). (Pubitemid 41077116)
29. Nakano, I. et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumours, including brain tumour stem cells. J. Neurosci. Res 86, 48-60 (2008).
30. Kwiatkowski, N. et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat. Chem. Biol. 6, 359-368 (2010).
31. Nezu, J., Oku, A., Jones, M. H. & Shimane, M. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45, 327-331 (1997). (Pubitemid 27467623)
32. Lopez-Borges, S. & Lazo, P. A. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene 19, 3656-3664 (2000). (Pubitemid 30608487)
33. Valbuena, A., Vega, F. M., Blanco, S. & Lazo, P. A. p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol. Cell Biol. 26, 4782-4793 (2006). (Pubitemid 43955797)
34. Valbuena, A. et al. Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer 58, 303-309 (2007). (Pubitemid 350051503)
35. Valbuena, A., Lopez-Sanchez, I. & Lazo, P. A. Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS One 3, e1642 (2008).
36. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
37. Chin, K. et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006). (Pubitemid 44854748)
38. Fan, C. et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (2006). (Pubitemid 44200649)
39. Ochocka, A. M. et al. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett. 583, 621-626 (2009).
40. Demidova, A. R., Aau, M. Y., Zhuang, L. & Yu, Q. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control. J. Biol. Chem. 284, 4132-4139 (2009).
41. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008). (Pubitemid 351655175)
42. Chen, Z. M., Xu, Z., Collins, R., Li, W. X. & Peto, R. Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA 278, 1500-1504 (1997). (Pubitemid 27488277)
43. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001). (Pubitemid 32743979)
44. Emery, C. M. et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411-20416 (2009).
45. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
46. Comin-Anduix, B. et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 16, 6040-6048 (2010).
47. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008). (Pubitemid 351723664)
48. Hoeflich, K. P. et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042-3051 (2009).
49. Zhu, J. et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet. 40, 854-861 (2008). (Pubitemid 351913653)
50. Wang, K., Narayanan, M., Zhong, H., Tompa, M. & Schadt, E. E. Meta-analysis of inter-species liver co-expression networks elucidates traits associated with common human diseases. PLoS Comput. Biol. 5, e1000616 (2009).
51. Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101-104 (2011).
52. Barlési, F. et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br. J. Cancer 93, 450-452 (2005). (Pubitemid 43080019)
53. Martins, S. J., Takagaki, T. Y., Silva, A. G., Gallo, C. P., Silva, F. B. & Capelozzi, V. L. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 64, 105-109 (2009).
54. Perner, S. et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J. Pathol. 217, 65-72 (2009).
55. Anagnostou, V. K., Syrigos, K. N., Bepler, G., Homer, R. J. & Rimm, D. L. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J. Clin. Oncol. 27, 271-278 (2009).
56. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
57. Barbosa-Morais, N. L. et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 38, e17 (2010).
58. Churchill, G. A. & Doerge, R. W. Empirical threshold values for quantitative trait mapping. Genetics 138, 963-971 (1994). (Pubitemid 24337818)
59. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001). (Pubitemid 32397092)
60. Maere, S., Heymans, K. & Kuiper, M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448-3449 (2005). (Pubitemid 41222459)